Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies

E. L. Nurmi, S. L. Spilman, F. Whelan, L. L. Scahill, M. G. Aman, C. J. McDougle, L. E. Arnold, B. Handen, C. Johnson, D. G. Sukhodolsky, D. J. Posey, L. Lecavalier, K. A. Stigler, L. Ritz, Elaine Tierney, B. Vitiello, J. T. McCracken

Research output: Contribution to journalArticle

Abstract

Second-generation antipsychotic exposure, in both children and adults, carries significant risk for excessive weight gain that varies widely across individuals. We queried common variation in key energy balance genes (FTO, MC4R, LEP, CNR1, FAAH) for their association with weight gain during the initial 8 weeks in the two NIMH Research Units on Pediatric Psychopharmacology Autism Network trials (N=225) of risperidone for treatment of irritability in children/adolescents aged 4-17 years with autism spectrum disorders. Variants in the cannabinoid receptor (CNR)-1 promoter (P=1.0×10-6), CNR1 (P=9.6×10-5) and the leptin (LEP) promoter (P=1.4×10 -4) conferred robust-independent risks for weight gain. A model combining these three variants was highly significant (P=1.3×10 -9) with a 0.85 effect size between lowest and highest risk groups. All results survived correction for multiple testing and were not dependent on dose, plasma level or ethnicity. We found no evidence for association with a reported functional variant in the endocannabinoid metabolic enzyme, fatty acid amide hydrolase, whereas body mass index-associated single-nucleotide polymorphisms in FTO and MC4R showed only trend associations. These data suggest a substantial genetic contribution of common variants in energy balance regulatory genes to individual antipsychoticassociated weight gain in children and adolescents, which supersedes findings from prior adult studies. The effects are robust enough to be detected after only 8 weeks and are more prominent in this largely treatment naive population. This study highlights compelling directions for further exploration of the pharmacogenetic basis of this concerning multifactorial adverse event.

Original languageEnglish (US)
Article numbere274
JournalTranslational Psychiatry
Volume3
DOIs
StatePublished - 2013

Fingerprint

Risperidone
Autistic Disorder
Antipsychotic Agents
Weight Gain
Leptin
Genes
National Institute of Mental Health (U.S.)
Psychopharmacology
Cannabinoid Receptors
Endocannabinoids
Pharmacogenetics
Regulator Genes
Single Nucleotide Polymorphism
Body Mass Index
Pediatrics
Enzymes
Therapeutics
Research
Population

Keywords

  • Autistic disorder
  • Children
  • CNR1
  • Leptin
  • Risperidone
  • Weight gain

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Cellular and Molecular Neuroscience

Cite this

Nurmi, E. L., Spilman, S. L., Whelan, F., Scahill, L. L., Aman, M. G., McDougle, C. J., ... McCracken, J. T. (2013). Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Translational Psychiatry, 3, [e274]. https://doi.org/10.1038/tp.2013.26

Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. / Nurmi, E. L.; Spilman, S. L.; Whelan, F.; Scahill, L. L.; Aman, M. G.; McDougle, C. J.; Arnold, L. E.; Handen, B.; Johnson, C.; Sukhodolsky, D. G.; Posey, D. J.; Lecavalier, L.; Stigler, K. A.; Ritz, L.; Tierney, Elaine; Vitiello, B.; McCracken, J. T.

In: Translational Psychiatry, Vol. 3, e274, 2013.

Research output: Contribution to journalArticle

Nurmi, EL, Spilman, SL, Whelan, F, Scahill, LL, Aman, MG, McDougle, CJ, Arnold, LE, Handen, B, Johnson, C, Sukhodolsky, DG, Posey, DJ, Lecavalier, L, Stigler, KA, Ritz, L, Tierney, E, Vitiello, B & McCracken, JT 2013, 'Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies', Translational Psychiatry, vol. 3, e274. https://doi.org/10.1038/tp.2013.26
Nurmi, E. L. ; Spilman, S. L. ; Whelan, F. ; Scahill, L. L. ; Aman, M. G. ; McDougle, C. J. ; Arnold, L. E. ; Handen, B. ; Johnson, C. ; Sukhodolsky, D. G. ; Posey, D. J. ; Lecavalier, L. ; Stigler, K. A. ; Ritz, L. ; Tierney, Elaine ; Vitiello, B. ; McCracken, J. T. / Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. In: Translational Psychiatry. 2013 ; Vol. 3.
@article{8bf4718025a143588c7cdcdcf470f0e7,
title = "Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies",
abstract = "Second-generation antipsychotic exposure, in both children and adults, carries significant risk for excessive weight gain that varies widely across individuals. We queried common variation in key energy balance genes (FTO, MC4R, LEP, CNR1, FAAH) for their association with weight gain during the initial 8 weeks in the two NIMH Research Units on Pediatric Psychopharmacology Autism Network trials (N=225) of risperidone for treatment of irritability in children/adolescents aged 4-17 years with autism spectrum disorders. Variants in the cannabinoid receptor (CNR)-1 promoter (P=1.0×10-6), CNR1 (P=9.6×10-5) and the leptin (LEP) promoter (P=1.4×10 -4) conferred robust-independent risks for weight gain. A model combining these three variants was highly significant (P=1.3×10 -9) with a 0.85 effect size between lowest and highest risk groups. All results survived correction for multiple testing and were not dependent on dose, plasma level or ethnicity. We found no evidence for association with a reported functional variant in the endocannabinoid metabolic enzyme, fatty acid amide hydrolase, whereas body mass index-associated single-nucleotide polymorphisms in FTO and MC4R showed only trend associations. These data suggest a substantial genetic contribution of common variants in energy balance regulatory genes to individual antipsychoticassociated weight gain in children and adolescents, which supersedes findings from prior adult studies. The effects are robust enough to be detected after only 8 weeks and are more prominent in this largely treatment naive population. This study highlights compelling directions for further exploration of the pharmacogenetic basis of this concerning multifactorial adverse event.",
keywords = "Autistic disorder, Children, CNR1, Leptin, Risperidone, Weight gain",
author = "Nurmi, {E. L.} and Spilman, {S. L.} and F. Whelan and Scahill, {L. L.} and Aman, {M. G.} and McDougle, {C. J.} and Arnold, {L. E.} and B. Handen and C. Johnson and Sukhodolsky, {D. G.} and Posey, {D. J.} and L. Lecavalier and Stigler, {K. A.} and L. Ritz and Elaine Tierney and B. Vitiello and McCracken, {J. T.}",
year = "2013",
doi = "10.1038/tp.2013.26",
language = "English (US)",
volume = "3",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies

AU - Nurmi, E. L.

AU - Spilman, S. L.

AU - Whelan, F.

AU - Scahill, L. L.

AU - Aman, M. G.

AU - McDougle, C. J.

AU - Arnold, L. E.

AU - Handen, B.

AU - Johnson, C.

AU - Sukhodolsky, D. G.

AU - Posey, D. J.

AU - Lecavalier, L.

AU - Stigler, K. A.

AU - Ritz, L.

AU - Tierney, Elaine

AU - Vitiello, B.

AU - McCracken, J. T.

PY - 2013

Y1 - 2013

N2 - Second-generation antipsychotic exposure, in both children and adults, carries significant risk for excessive weight gain that varies widely across individuals. We queried common variation in key energy balance genes (FTO, MC4R, LEP, CNR1, FAAH) for their association with weight gain during the initial 8 weeks in the two NIMH Research Units on Pediatric Psychopharmacology Autism Network trials (N=225) of risperidone for treatment of irritability in children/adolescents aged 4-17 years with autism spectrum disorders. Variants in the cannabinoid receptor (CNR)-1 promoter (P=1.0×10-6), CNR1 (P=9.6×10-5) and the leptin (LEP) promoter (P=1.4×10 -4) conferred robust-independent risks for weight gain. A model combining these three variants was highly significant (P=1.3×10 -9) with a 0.85 effect size between lowest and highest risk groups. All results survived correction for multiple testing and were not dependent on dose, plasma level or ethnicity. We found no evidence for association with a reported functional variant in the endocannabinoid metabolic enzyme, fatty acid amide hydrolase, whereas body mass index-associated single-nucleotide polymorphisms in FTO and MC4R showed only trend associations. These data suggest a substantial genetic contribution of common variants in energy balance regulatory genes to individual antipsychoticassociated weight gain in children and adolescents, which supersedes findings from prior adult studies. The effects are robust enough to be detected after only 8 weeks and are more prominent in this largely treatment naive population. This study highlights compelling directions for further exploration of the pharmacogenetic basis of this concerning multifactorial adverse event.

AB - Second-generation antipsychotic exposure, in both children and adults, carries significant risk for excessive weight gain that varies widely across individuals. We queried common variation in key energy balance genes (FTO, MC4R, LEP, CNR1, FAAH) for their association with weight gain during the initial 8 weeks in the two NIMH Research Units on Pediatric Psychopharmacology Autism Network trials (N=225) of risperidone for treatment of irritability in children/adolescents aged 4-17 years with autism spectrum disorders. Variants in the cannabinoid receptor (CNR)-1 promoter (P=1.0×10-6), CNR1 (P=9.6×10-5) and the leptin (LEP) promoter (P=1.4×10 -4) conferred robust-independent risks for weight gain. A model combining these three variants was highly significant (P=1.3×10 -9) with a 0.85 effect size between lowest and highest risk groups. All results survived correction for multiple testing and were not dependent on dose, plasma level or ethnicity. We found no evidence for association with a reported functional variant in the endocannabinoid metabolic enzyme, fatty acid amide hydrolase, whereas body mass index-associated single-nucleotide polymorphisms in FTO and MC4R showed only trend associations. These data suggest a substantial genetic contribution of common variants in energy balance regulatory genes to individual antipsychoticassociated weight gain in children and adolescents, which supersedes findings from prior adult studies. The effects are robust enough to be detected after only 8 weeks and are more prominent in this largely treatment naive population. This study highlights compelling directions for further exploration of the pharmacogenetic basis of this concerning multifactorial adverse event.

KW - Autistic disorder

KW - Children

KW - CNR1

KW - Leptin

KW - Risperidone

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=84879952310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879952310&partnerID=8YFLogxK

U2 - 10.1038/tp.2013.26

DO - 10.1038/tp.2013.26

M3 - Article

C2 - 23799528

AN - SCOPUS:84879952310

VL - 3

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

M1 - e274

ER -